Clinical Trials Logo

Myopia clinical trials

View clinical trials related to Myopia.

Filter by:

NCT ID: NCT05803863 Not yet recruiting - Myopia Clinical Trials

Efficacy Comparison of 2 Low-dose Atropine Eye Drops in Vietnamese Children Myopia Management

Start date: April 15, 2023
Phase: Phase 4
Study type: Interventional

The goal of this clinical trial is to compare the efficacy of 2 low-dose atropine drops (0,01%; 0,05%) in Vietnamese children. The main questions it aims to answer are: 1. How is the difference in efficacy among 3 groups: atropine 0,01% vs 0,05% vs spectacles? 2. How is the difference in side effects among 3 groups: atropine 0,01% vs 0,05% vs spectacles? 3. How is the difference in rebound phenomena between 2 atropine groups?

NCT ID: NCT05803174 Active, not recruiting - High Myopia Clinical Trials

Screening and Identification of Biomarkers for High Myopia by a Rapid Method

Start date: March 20, 2023
Phase:
Study type: Observational

To screen and identify sensitive biomarkers for high myopia via a robust, convenient, and cost-effective approach according to the association between high myopia and concentration of biomarkers in tear fluid, saliva and blood among adults and children.

NCT ID: NCT05790928 Completed - Myopia Clinical Trials

Air Optix Night and Day Aqua (AONDA) Retrospective Study 1

Start date: March 25, 2023
Phase:
Study type: Observational

The purpose of this study is to assess long term performance and safety of AONDA in a real world setting when worn as daily wear or continuous wear for vision correction. This study will be used to support AONDA's marketability in Europe and other locations.

NCT ID: NCT05786586 Recruiting - Myopia Clinical Trials

650nm Low-level Red-light for Myopia Control and Prevention in Children

Start date: March 26, 2023
Phase: N/A
Study type: Interventional

A multicenter randomized controlled trial, evaluating the efficacy and safety of 650nm low-level red-light irradiation for myopia control and prevention in children. Participants included children(aged 6 to 12 years, spherical equivalent error of 0.5D or below) who are already myopic at recruitment, and those who are of Emmetropia or low hyperopia.

NCT ID: NCT05779072 Completed - Myopia Clinical Trials

Dual Focus Soft Contact Lens Wear Cessation Study

Start date: March 1, 2019
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate the effect of ceasing treatment with dual focus soft contact lenses.

NCT ID: NCT05778409 Recruiting - Myopia Clinical Trials

To Study the Effects of Cordyceps Cicadae on Vision Care

Start date: March 8, 2023
Phase: Early Phase 1
Study type: Interventional

Cordyceps cicadae is a traditional Asian herbal medicine with a variety of bioactive substances and curative effects similar to Cordyceps Cicadae, and it has been reported that anti-dry eye and eye protection ingredients can be extracted. With the advancement of civilization, the number of patients with high myopia is increasing year by year and suffers from complications of dry eye or other eye diseases. In this study, the subjects were provided with cicadae extract or placebo in a double-blind manner, tracked the degree of visual fatigue by regular questionnaires, and measured for visual acuity, axial length and diopter. The purpose of this study is to investigate the effect of cicadae extract on visual acuity and visual fatigue, and to evaluate its potential as a health food ingredient.

NCT ID: NCT05778201 Recruiting - Myopia Clinical Trials

To Study the Effects of Baby Drink on Vision Care

Start date: March 8, 2023
Phase: Early Phase 1
Study type: Interventional

Baby Drink is a formula based on lutein, mixed with blueberry fermented liquid, vitamins and minerals. Lutein is an effective antioxidant to prevent retinal damage caused by blue light, but it cannot be produced in the human body and depends on dietary intake. Blueberry fermented liquid is rich in polyphenolic compounds with excellent antioxidant capacity and the potential to reduce oxidative damage to eye cells caused by ultraviolet rays. With the prevalence of 3C products, myopia patients are increasing year by year in various regions, and suffer from eye diseases or vision loss with different degrees of complications. In this study, the subjects were provided with Baby Drink and tracked the degree of visual fatigue by regular questionnaires, and measured for visual acuity, axial length and diopter. The aim of this study is to investigate the protection of Baby Drink on visual acuity and visual fatigue.

NCT ID: NCT05773118 Withdrawn - Myopia, Progressive Clinical Trials

A Unified Index to Predict the Success Probability of Myopia Control

Start date: January 2025
Phase: N/A
Study type: Interventional

Orthokeratology lenses (OK-lens) and multifocal contact lenses (MFCL) are optical devices designed to slow down the progression of myopia. Both treatments a long-term commitment from doctors and patients. This study aims to develop a unified index to predict the success probability of myopia control at the early stage of treatment.

NCT ID: NCT05768152 Not yet recruiting - Eye Diseases Clinical Trials

Repeated Low-Level Red-Light Therapy Shortens Axial Length

Start date: March 2023
Phase: N/A
Study type: Interventional

The purpose of this clinical trial is to investigate the incidence and magnitude of axial length shortening after repeated low-level red-light therapy in high myopia children and teenagers.

NCT ID: NCT05761795 Not yet recruiting - Myopia, Progressive Clinical Trials

Efficacy of IVMED-85 on Pediatric Myopia

Start date: February 2024
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this clinical trial is to evaluate the safety and preliminary efficacy of a 1-year course of IVMED-85 eye drops for the treatment of pediatric myopia by assessing its safety effects on visual acuity and its effect on the change and/or progression of myopia. The main question[s] it aims to answer are: - Does IVMED 85 improve visual acuity - Does IVMED 85 slow or otherwise change the progression of myopia Participants will use eyedrops twice a day for one year. Researchers will compare IVMED 85 to a placebo.